GW Pharmaceuticals has ended the week on quite a high after the UK drugmaker unveiled positive preliminary late-stage data for its cannabis-based drug Sativex in multiple sclerosis spasticity.
Read MoreGilead Sciences is planning to snatch CV Therapeutics from under the nose of Astellas Pharma and has had a cash bid, which tops the hostile offer made by the Japanese drugmaker by 25%, accepted by the board.
Read MorePfizer says that it has called an early halt to a late-stage trial of its advanced kidney cell carcinoma drug Sutent after the therapy proved highly effective as a treatment for a rare form of pancreatic cancer.
Read MoreRoche looks to have finally gained control of the 44.2% stake in Genentech it did not already own but it has taken a $95 per share offer to clinch the deal.
Read MoreDespite the economic slowdown, the USA’s pharmaceutical research and biotechnology companies invested a record $65.2 billion last year in R&D, an increase of $2 billion from 2007.
Read More
